London, UK -- (MARKET WIRE) -- May 1, 2007 --FOR IMMEDIATE RELEASE
Addendum to results announcement
SkyePharma PLC (LSE:SKP; NASDAQ: SKYE), LONDON, ENGLAND, 1 May 2007
This announcement is to correct a minor typographical error on the results
announcement of 26 April 2007.
Whilst the total figures for earnings per share for 2006 were correctly stated
in the original announcement, the split between pre-exceptional and exceptional
earnings per share for 2006 was incorrectly stated on the face of the profit and
loss account. The figures were correctly stated in Note 6 to the original
announcement, an extract of which is set out below:
Earnings per share
Year to Year to
31 December 2006 31 December 2005
(restated)
Continuing operations
Loss per Ordinary Share
before exceptional items (3.4)p (2.5)p
Exceptional tems 0.9p (0.8)p
------- -------
Basic and diluted loss
per Ordinary Share (2.5)p (3.3)p
------- -------
Continuing and discontinued operations
Loss per Ordinary Share before
exceptional items (6.4)p (4.7)p
Exceptional items (4.0)p (3.4)p
------- -------
Basic and diluted loss per
Ordinary Share (10.4)p (8.1)p
------- -------
For further information please contact:
SkyePharma PLC
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer +44 207 491 1777
Peter Grant, Finance Director
Financial Dynamics (London enquiries)
David Yates / Deborah Scott +44 207 831 3113
Trout Group (US enquiries)
Christine Labaree / Seth Lewis +1 617 583 1308
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new
formulations of known molecules to provide a clinical advantage and life-cycle
extension. The Group has ten approved products in the areas of oral, inhalation
and topical delivery. The Group's products are marketed throughout the world by
leading pharmaceutical companies. For more information, visit
www.skyepharma.com.
This information is provided by RNS
The company news service from the London Stock Exchange